Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-08-06 22:42:08 ET Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Conference Call August 01, 2023, 04:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu S...
2023-08-01 08:05:53 ET Astellas Pharma press release ( OTCPK:ALPMF ): Q1 GAAP EPS of ¥28.88. Revenue of ¥374.99B (-1.8% Y/Y). For further details see: Astellas Pharma GAAP EPS of ¥28.88, revenue of ¥374.99B
2023-07-21 19:02:28 ET Summary Merck & Co., Inc. has increased reliance on Keytruda and Gardasil. Merck became a Seeking Alpha Quant system Strong Buy on July 11 for no clear reason. Clinical catalysts have so far not moved Merck stock upward. Our previous cove...
2023-06-18 07:05:00 ET Summary San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Cholesgen (Shanghai) formed a three-year collaboration with AstraZeneca to develop ...
2023-05-30 15:02:46 ET Summary Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an acquisition that is targeted to close in the third calendar q...
2023-05-25 07:42:54 ET Summary Patients with upper GI cancers are in dire need of new therapeutic options. Astellas is sitting on a shoo-in approval for a brand new targeted therapy based on highly promising clinical trial data. An approval in this space could mean important n...
2023-05-18 08:20:30 ET FibroGen's ( NASDAQ: FGEN ) oral drug roxadustat was good as recombinant erythropoietin alfa (SEPO) in improving hemoglobin (Hb) level in a phase 3 trial to treat anemia in patients receiving chemotherapy for non-myeloid malignancies in China. Anemia ...
2023-05-12 14:42:30 ET The US FDA has granted approval to Astellas Pharma's ( OTCPK:ALPMF )( OTCPK:ALPMY ) Veozah (fezolinetant) for hot flashes associated with menopause. The agency noted that the drug is the first neurokinin 3 (NK3) receptor antagonist approved for the condi...
2023-05-09 08:56:49 ET Leading drugmakers are prepping for a legal fight against recently implemented U.S. drug pricing reforms which bring negotiating power to Medicare for the first time ever, Reuters reported Tuesday, citing industry sources. In March, the Centers for Medicare &a...
2023-05-01 09:12:47 ET Apellis Pharmaceuticals ( NASDAQ: APLS ) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio ( ISEE ) agreed to be sold to Astellas Pharma ( OTCPK:ALPMF ) for $5.9 billion on Sunday, according to ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...